Thermo Fisher Scientific Inc. (NYSE:TMO) saw unusually large options trading activity on Wednesday. Stock investors purchased 5,961 put options on the stock. This represents an increase of 1,383% compared to the average volume of 402 put options.

Several research firms have commented on TMO. BTIG Research increased their price target on shares of Thermo Fisher Scientific to $310.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 30th. Needham & Company LLC began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, January 2nd. They set a “strong-buy” rating and a $271.00 price target for the company. Bank of America reissued a “buy” rating and set a $300.00 price target (up from $285.00) on shares of Thermo Fisher Scientific in a research report on Tuesday. Finally, UBS Group increased their price target on shares of Thermo Fisher Scientific to $305.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $289.92.

Shares of Thermo Fisher Scientific stock opened at $257.51 on Thursday. The company has a market capitalization of $110.75 billion, a P/E ratio of 23.16, a P/E/G ratio of 1.83 and a beta of 1.13. The company has a quick ratio of 1.24, a current ratio of 1.73 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a 52 week low of $202.83 and a 52 week high of $282.98.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.06. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue was up 7.6% on a year-over-year basis. During the same period last year, the firm posted $2.79 EPS. Analysts expect that Thermo Fisher Scientific will post 12.15 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 16th. Investors of record on Friday, March 15th were given a $0.19 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. This represents a $0.76 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 5,400 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $251.51, for a total transaction of $1,358,154.00. Following the completion of the sale, the senior vice president now directly owns 31,846 shares of the company’s stock, valued at $8,009,587.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Peter E. Hornstra sold 5,920 shares of the stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $250.00, for a total transaction of $1,480,000.00. Following the sale, the chief accounting officer now directly owns 17,057 shares of the company’s stock, valued at $4,264,250. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,927 shares of company stock worth $9,388,124. 0.49% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in TMO. Point72 Asset Management L.P. raised its position in shares of Thermo Fisher Scientific by 473.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 57,300 shares of the medical research company’s stock valued at $13,986,000 after purchasing an additional 47,300 shares during the last quarter. AQR Capital Management LLC raised its position in Thermo Fisher Scientific by 71.4% during the 3rd quarter. AQR Capital Management LLC now owns 1,499,423 shares of the medical research company’s stock worth $365,979,000 after buying an additional 624,602 shares during the last quarter. Resources Management Corp CT ADV purchased a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $213,000. Koshinski Asset Management Inc. raised its position in Thermo Fisher Scientific by 118.4% during the 3rd quarter. Koshinski Asset Management Inc. now owns 7,291 shares of the medical research company’s stock worth $1,780,000 after buying an additional 3,952 shares during the last quarter. Finally, Equitable Trust Co. raised its position in Thermo Fisher Scientific by 11.4% during the 3rd quarter. Equitable Trust Co. now owns 8,525 shares of the medical research company’s stock worth $2,081,000 after buying an additional 875 shares during the last quarter. 88.66% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Thermo Fisher Scientific Sees Unusually High Options Volume (TMO)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/04/18/thermo-fisher-scientific-sees-unusually-high-options-volume-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Portfolio Manager

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.